Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells $914,400.00 in Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Sarah Gheuens sold 30,000 shares of the stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $30.48, for a total value of $914,400.00. Following the transaction, the insider owned 54,645 shares in the company, valued at $1,665,579.60. The trade was a 35.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Agios Pharmaceuticals Stock Performance

NASDAQ:AGIO opened at $32.27 on Friday. Agios Pharmaceuticals, Inc. has a 52 week low of $22.24 and a 52 week high of $46.00. The firm’s 50-day simple moving average is $34.75 and its 200 day simple moving average is $31.01. The firm has a market cap of $1.93 billion, a price-to-earnings ratio of -4.60 and a beta of 0.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. The business had revenue of $44.75 million during the quarter, compared to the consensus estimate of $26.39 million. Sell-side analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.12 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently issued reports on AGIO shares. Royal Bank Of Canada increased their target price on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a report on Tuesday, July 7th. Citigroup upped their price target on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Bank of America lifted their price target on shares of Agios Pharmaceuticals from $40.00 to $46.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, June 24th. Finally, HC Wainwright boosted their target price on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Five investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $41.25.

Institutional Investors Weigh In On Agios Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of Agios Pharmaceuticals during the 2nd quarter valued at $239,582,000. Wellington Management Group LLP lifted its stake in shares of Agios Pharmaceuticals by 485.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after buying an additional 2,049,287 shares in the last quarter. MPM Bioimpact LLC bought a new position in shares of Agios Pharmaceuticals in the fourth quarter worth $35,478,000. State Street Corp boosted its stake in Agios Pharmaceuticals by 37.4% in the 4th quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock worth $84,604,000 after purchasing an additional 845,433 shares during the period. Finally, TCG Crossover Management LLC boosted its stake in Agios Pharmaceuticals by 105.2% in the 3rd quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock worth $57,402,000 after purchasing an additional 733,038 shares during the period.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.